104 completed, 25 terminated, 13 unknown, 6 withdrawn. 112 Phase 1, 29 Phase 2, 8 Not applicable, 5 Phase 3, 2 Phase 4.
Follow Tumors: new trials by email Literature Review of Tumors trials Research Report on Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection Tumors, PET / CT | Completed | Lanzhou University Second Hospital | 27 | 2024-07-01 | 2025-04-25 | |
| HP Pyruvate MRI in Cancers Hyperpolarized 13C-Pyruvate - Image, Warburg Effect | Phase 1 / Phase 2 | Recruiting | University of Maryland, Baltimore | 25 | 2024-06-24 | 2025-09-22 |
| A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors 68Ga-DOTA-GPFAPI-04 PET/CT - Cancer, Malignant Neoplasm | Not applicable | Unknown | Guangdong Provincial People's Hospital | 30 | 2024-01-13 | 2024-01-22 |
| Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors ZN-c3, Bevacizumab, Pembrolizumab - Tumors, Ovarian Cancer | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2022-12-14 | 2023-06-15 | |
| POWER UP: Participating Online While Exercising to Recover Using Play Focus Groups, Pilot randomized controlled trial - Exercise, Central Nervous System Tumors | Not applicable | Terminated | M.D. Anderson Cancer Center | 17 | 2022-05-04 | 2025-08-05 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) nab-sirolimus - Tumor, Tumor, Solid | Phase 2 | Completed | Aadi Bioscience, Inc. | 128 | 2022-03-10 | 2026-10-28 |
| Cohort of Tumors With POLE/D1 Mutation Tumors, POLE Exonuclease Domain Mutation | Unknown | Federation Francophone de Cancerologie Digestive | 100 | 2021-10-05 | 2024-07-08 | |
| XACT ACE Observational Registry Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T - Tumors | Unknown | Xact Robotics Ltd. | 500 | 2021-10-01 | 2022-10-21 | |
| Research on the Application and Mechanism of New Biological Probes in Biomedicine No intervention - Tumors, Cardiovascular Diseases | Completed | Nanfang Hospital, Southern Medical University | 737 | 2021-08-03 | 2022-08-22 | |
| CDK4/6 Tumor, Abemaciclib, Paclitaxel abemaciclib+paclitaxel - Tumors | Phase 1 / Phase 2 | Completed | Yonsei University | 30 | 2021-02-25 | 2024-12-18 |
| ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling Alectinib, Atezolizumab, Avelumab - Cancer, Tumors | Phase 2 | Recruiting | Ulrik Lassen | 300 | 2020-08-24 | 2025-07-25 |
| A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors ASP1650 - Incurable Platinum Refractory Germ Cell Tumors, Tumors | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 19 | 2019-03-19 | 2024-11-13 |
| Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors Standard of Care - Tumors | Recruiting | M.D. Anderson Cancer Center | 300 | 2018-12-20 | 2026-10-07 | |
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors BMS-986226, Nivolumab, Ipilimumab - Cancer, Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 80 | 2017-09-01 | 2023-02-28 |
| Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs TAS-102, Temozolomide, Filgrastim - Neuroendocrine Tumors, Neoplasms | Phase 1 | Terminated | University of Wisconsin, Madison | 18 | 2017-08-22 | 2022-09-23 |
| Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer IT-141 - Cancer, Neoplasms | Phase 1 | Terminated | Intezyne Technologies, Inc. | 10 | 2017-03-23 | 2020-12-22 |
| Assay Development for Cancer Biomarkers Venesection, Urine collection, Sputum collection - Tumors | Unknown | King's College London | 400 | 2016-11-01 | 2016-11-25 | |
| The Drug Rediscovery Protocol (DRUP Trial) Panitumumab, Olaparib, Dabrafenib - Cancer, Tumors | Phase 2 | Recruiting | The Netherlands Cancer Institute | 1550 | 2016-08-01 | 2024-01-24 |
| Point of Care 3D Ultrasound for Various Applications: A Pilot Study Appendicitis, Evidence of Cholecystectomy | Completed | Duke University | 174 | 2016-07-01 | 2024-05-21 | |
| Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors Lenvatinib, Midazolam - Tumors | Phase 1 | Completed | Eisai Inc. | 51 | 2016-04-18 | 2019-08-28 |
Showing 20 of 154. Sign in to see all of them.
Neoplasms (154) · Neoplasm Metastasis (15) · Lymphoma (11) · Breast Neoplasms (8) · Carcinoma (7) · Lung Neoplasms (6) · Melanoma (5) · Ovarian Neoplasms (5) · Pancreatic Neoplasms (5) · Prostatic Neoplasms (5) · Colorectal Neoplasms (4) · Hematologic Neoplasms (4) · Multiple Myeloma (4) · Recurrence (4) · Sarcoma (4)
Neoplasms by Histologic Type (33) · Neoplasms by Site (30) · Pathological Conditions, Signs and Symptoms (27) · Pathologic Processes (23) · Hemic and Lymphatic Diseases (20) · Immune System Diseases (16) · Immunoproliferative Disorders (16) · Lymphoproliferative Disorders (16) · Neoplastic Processes (16) · Lymphatic Diseases (14) · Neoplasms, Glandular and Epithelial (14) · Urogenital Diseases (14) · Skin Diseases (12) · Skin and Connective Tissue Diseases (12) · Female Urogenital Diseases (11)
Paclitaxel (7) · Carboplatin (6) · Bevacizumab (4) · Docetaxel (4) · Trastuzumab (4) · atezolizumab (4) · lenvatinib (4) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (3) · Capecitabine (3) · Gemcitabine (3) · Irinotecan (3) · Panitumumab (3) · Topotecan (3) · brivanib (3) · epothilone B (3)
Amgen (12) · Bristol-Myers Squibb (8) · Novartis Pharmaceuticals (6) · Merck Sharp & Dohme LLC (5) · AstraZeneca (4) · Eisai Inc. (3) · M.D. Anderson Cancer Center (3) · Sanofi (3) · Universitätsmedizin Mannheim (3) · Wyeth is now a wholly owned subsidiary of Pfizer (3) · AEterna Zentaris (2) · Agennix (2) · Astellas Pharma Inc (2) · Bayer (2) · Biogen (2)
United States (96) · Canada (15) · France (11) · United Kingdom (10) · Japan (9) · Germany (7) · Italy (7) · Spain (6) · Belgium (5) · China (5) · Netherlands (5) · Australia (4) · Israel (3) · South Korea (3) · Switzerland (3)
Gerald Batist, MD (2) · Gregory Reid, MSc, MBA (2) · Nina Bhardwaj, MD, PhD (2) · Shimon Slavin, MD (2) · Aaron Mansfield, MD (1) · Abby Maizel, MD,PhD (1) · Anthony Tolcher, M.D. (1)
PMID 31401903, PMID 10080202, PMID 10939721, PMID 11274063, PMID 11535447, PMID 12878240, PMID 15019336, PMID 15234135, PMID 15523957, PMID 16622259, PMID 16818691, PMID 17517626, PMID 17557949, PMID 17701265, PMID 18077538, PMID 18202410, PMID 19192962, PMID 19203894, PMID 19238148, PMID 20007996, PMID 20110052, PMID 20306901, PMID 22210018, PMID 22234637, PMID 22371427, PMID 22884766, PMID 23400739, PMID 23643139, PMID 25428504, PMID 25795637, PMID 26155941, PMID 26755520, PMID 27139036, PMID 28039265, PMID 28962909, PMID 29423515, PMID 29980894, PMID 30073642, PMID 30077125, PMID 30219915, PMID 30242306, PMID 30922731, PMID 31204078, PMID 31358540, PMID 31542806, PMID 31647026, PMID 31961766, PMID 32067158, PMID 32167863, PMID 32554315
2017 (2), 2014 (1), 2015 (1)